169 related articles for article (PubMed ID: 15716549)
1. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
Konishi T; Yoshiyama Y; Takamori M; Saida T
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):448-50. PubMed ID: 15716549
[TBL] [Abstract][Full Text] [Related]
2. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
Tada M; Shimohata T; Tada M; Oyake M; Igarashi S; Onodera O; Naruse S; Tanaka K; Tsuji S; Nishizawa M
J Neurol Sci; 2006 Aug; 247(1):17-20. PubMed ID: 16631797
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.
Wakata N; Saito T; Tanaka S; Hirano T; Oka K
Clin Neurol Neurosurg; 2003 Dec; 106(1):5-8. PubMed ID: 14643908
[TBL] [Abstract][Full Text] [Related]
4. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH; Shin HY; Kim SM
Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus.
Nagaishi A; Yukitake M; Kuroda Y
Intern Med; 2008; 47(8):731-6. PubMed ID: 18421189
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
9. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis.
Tao X; Wang W; Jing F; Wang Z; Chen Y; Wei D; Huang X
Neurol Sci; 2017 Feb; 38(2):325-330. PubMed ID: 27873026
[TBL] [Abstract][Full Text] [Related]
11. A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis.
Ahn SW; Joo IS; Kim BJ; Sung JJ; Kang SY; Oh J; Minn YK; Suh BC; Oh SY; Hong YH; Nam TS; Seok JI; Park YE; Shin HY; Cho EB; Shin JY; Seok HY; Park JS; Min JH; Seok JM; Kim BJ
J Neurol Sci; 2017 Aug; 379():271-275. PubMed ID: 28716258
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic efficacy and safety of tacrolimus for intractable myasthenia gravis: a report of 36 patients].
Feng HY; Liu WB; Qiu L; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(45):3190-2. PubMed ID: 22333101
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis.
Itani K; Nakamura M; Wate R; Kaneko S; Fujita K; Iida S; Morise S; Murakami A; Kunieda T; Takenouchi N; Yakushiji Y; Kusaka H
Neuromuscul Disord; 2021 Jun; 31(6):512-518. PubMed ID: 33903022
[TBL] [Abstract][Full Text] [Related]
15. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.
Yoshikawa H; Kiuchi T; Saida T; Takamori M
J Neurol Neurosurg Psychiatry; 2011 Sep; 82(9):970-7. PubMed ID: 21784757
[TBL] [Abstract][Full Text] [Related]
16. Clinical study of FK506 in patients with myasthenia gravis.
Konishi T; Yoshiyama Y; Takamori M; Yagi K; Mukai E; Saida T;
Muscle Nerve; 2003 Nov; 28(5):570-4. PubMed ID: 14571458
[TBL] [Abstract][Full Text] [Related]
17. [The clinical efficacy and safety of tacrolimus in patients with myasthenia gravis].
Chen YP; Wang W; Wang ZK; Wei DN; Zhang J
Zhonghua Nei Ke Za Zhi; 2013 Jul; 52(7):567-9. PubMed ID: 24266997
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
[TBL] [Abstract][Full Text] [Related]
19. Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis.
Nishida Y; Takahashi YK; Kanai T; Nose Y; Ishibashi S; Sanjo N; Uzawa A; Oda F; Ozawa Y; Kuwabara S; Noguchi E; Suzuki S; Nakahara J; Suzuki N; Ogawa T; Yokoyama K; Hattori N; Konno S; Fujioka T; Kawaguchi N; Hatanaka Y; Sonoo M; Kaneko J; Ogino M; Nishiyama K; Nomura K; Yokota T
Eur J Neurol; 2020 Jan; 27(1):100-104. PubMed ID: 31309642
[TBL] [Abstract][Full Text] [Related]
20. Adequate tacrolimus concentration for myasthenia gravis treatment.
Kanai T; Uzawa A; Kawaguchi N; Himuro K; Oda F; Ozawa Y; Kuwabara S
Eur J Neurol; 2017 Feb; 24(2):270-275. PubMed ID: 28102047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]